Skip to Main Content
TABLE 2

Progression to Daily Tobacco Use among Nondaily Ever Tobacco Users at Baseline in the 2014 and 2017 PATH Cohorts

Age at Baselinea2014 PATH Cohort2017 PATH CohortIncrease in New Daily Tobacco Use in 2017 Cohort
Nondaily Tobacco Users in 2014 (n)Progression from Nondaily to Daily Tobacco Use, 2016Nondaily Tobacco Users in 2017 (n)Progression from Nondaily to Daily Tobacco Use, 2019US Population Estimate
(N)
% of All New Daily Users
%c95% CIUS Population Estimate
(N)
%b95% CIUS Population Estimate
(N)
14–17 7051 4.8 4.3–5.5 775 504 8585 6.3 5.8–7.0 1 030 957 255 453 64.60 
18–21 2938 5.8 4.8–6.8 840 154 5587 6.3 5.6–7.1 971 496 131 342 33.20 
22–25 2369 5.2 4.4–6.1 721 298 2987 5.3 4.5–6.1 726 049 4751 1.20 
26–29 1181 5.6 4.4–7.1 681 767 1878 5.4 4.3–6.8 717 815 36 048 9.10 
30–34 1437 3.7 2.9–4.6 617 338 1563 3.5 2.6–4.6 585 341 −31 997 −8.10 
Total 14 976 4.9 4.5–5.4 3 636 060 20 600 5.3 4.9–5.8 4 031 657 395 597 100 
Age at Baselinea2014 PATH Cohort2017 PATH CohortIncrease in New Daily Tobacco Use in 2017 Cohort
Nondaily Tobacco Users in 2014 (n)Progression from Nondaily to Daily Tobacco Use, 2016Nondaily Tobacco Users in 2017 (n)Progression from Nondaily to Daily Tobacco Use, 2019US Population Estimate
(N)
% of All New Daily Users
%c95% CIUS Population Estimate
(N)
%b95% CIUS Population Estimate
(N)
14–17 7051 4.8 4.3–5.5 775 504 8585 6.3 5.8–7.0 1 030 957 255 453 64.60 
18–21 2938 5.8 4.8–6.8 840 154 5587 6.3 5.6–7.1 971 496 131 342 33.20 
22–25 2369 5.2 4.4–6.1 721 298 2987 5.3 4.5–6.1 726 049 4751 1.20 
26–29 1181 5.6 4.4–7.1 681 767 1878 5.4 4.3–6.8 717 815 36 048 9.10 
30–34 1437 3.7 2.9–4.6 617 338 1563 3.5 2.6–4.6 585 341 −31 997 −8.10 
Total 14 976 4.9 4.5–5.4 3 636 060 20 600 5.3 4.9–5.8 4 031 657 395 597 100 

Tobacco use means any cigarettes, e-cigarettes, cigars (traditional, filtered, regular), cigarillos, pipes, hookahs, snus, and smokeless tobacco.

a

Baseline for pre-JUUL cohort is 2014; baseline for JUUL-era cohort is 2017.

b

Percentage of nondaily tobacco users who progressed to daily use over a 2-year follow-up.

Close Modal

or Create an Account

Close Modal
Close Modal